Geron (GERN) Debt Ratio (2011 - 2026)

Geron (GERN) posted Debt Ratio of 0.22 for Q1 2026, up 7.07% sequentially from 0.21 in Q4 2025, and up 6.28% YoY from 0.21 in Q1 2025.

Geron (GERN) Debt Ratio (2011 - 2026) Analysis & Trends

Geron has reported Debt Ratio for 9 years, with the latest figure at 0.22 in Q1 2026.

Quarterly Debt Ratio rose 6.28% year-over-year to 0.22 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.22 (up 6.28% YoY) and the FY2025 annual result came in at 0.21, up 5.01% from the prior year.
Debt Ratio rose to 0.22 in Q1 2026 per GERN's latest filing, from 0.21 in the prior quarter.
Over five years, Debt Ratio peaked at 0.27 in Q4 2022 and troughed at 0.12 in Q1 2023.
A 5-year average of 0.2 and a median of 0.21 in 2025 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2022 and 2023: Debt Ratio soared 170.0% in 2022, then tumbled 52.16% in 2023.
Over 5 years, Debt Ratio stood at 0.27 in 2022, then retreated by 22.54% to 0.21 in 2023, then fell by 4.05% to 0.2 in 2024, then increased by 5.01% to 0.21 in 2025, then climbed by 7.07% to 0.22 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.22, 0.21, and 0.21 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.94 Bn	132.09 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.59 Bn	78.60 Bn	3.93 Bn	0.05
3	Argenx Se	65.67 Bn	60.49 Bn	1.37 Bn	-
4	Moderna	57.81 Bn	52.67 Bn	52.00 Mn	0.05
5	BeOne Medicines	42.25 Bn	37.15 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.76 Bn	28.45 Bn	992.69 Mn	-
7	BioNTech SE	28.41 Bn	10.02 Bn	668.28 Mn	0.03
8	Insmed	27.58 Bn	26.42 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.24 Bn	26.41 Bn	-	0.47
10	Geron	1.05 Mn	-299.80 Mn	-	0.23

Download Data